
    
      The study is a prospective, randomized, parallel-design, multicenter trial in patients â‰¥40
      years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion
      criteria will be randomized to 1 of 2 treatment groups

        -  A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone,
           equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or;

        -  Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times
           daily (QID) for 3 weeks
    
  